

Our Ref: 62/2023
JANUARY 2023

Re: Your request made under the Freedom of Information Act 2000

1. For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition:

Aflibercept - 924

Bevacizumab - 31

Brolucizumab - 0

Dexamethasone - 5

Faricimab - 14

Ranibizumab – Lucentis - 22

Ranibizumab – Ongavia - 0

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab – Ongavia

Unfortunately we are unable to answer Q2 as the system doesn't track whether a treatment is "new". **To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**